We investigated the effects of a new pyridoquinazoline
thromboxane synthetase inhibitor infused before administering
Escherichia Coli endotoxin into 18 anesthetized sheep with lung lymph
fistulas. In normal sheep increasing plasma
Ro 23-3423 concentrations were associated with increased plasma levels of
6-keto-PGF1 alpha, a reduced systemic vascular resistance (SVR, r = -0.80) and systemic arterial pressure (SAP, r = -0.92), the mean SAP falling from 80 to 50 mm Hg at the 20 and 30 mg/kg doses.
Endotoxin infused into normal sheep caused transient pulmonary vasoconstriction associated with increased TxB2 and
6-keto-PGF1 alpha levels while vasoconstriction and TxB2 increase were significantly inhibited by pretreatment with
Ro 23-3423 in a dose-dependent manner. When compared to controls, plasma and lymph levels of
6-keto-PGF1 alpha,
PGF2 alpha and
PGE2 after
endotoxin infusion were increased several-fold by administering
Ro 23-3423 up to plasma levels of 10 micrograms/ml. Doses over 30 mg/kg with blood levels above 10 micrograms/ml reduced plasma and lymph levels of
6-keto-PGF1 alpha,
PGF2 alpha and
PGE2, suggesting
cyclooxygenase blockade at this dose. The peak
6-keto-PGF1 alpha levels at 60 min after
endotoxin infusion in sheep with
Ro-23-3423 levels below 10 micrograms/ml were associated with the greatest systemic
hypotension due to a reduced SVR (r = -0.86). After
endotoxin infusion the
leukotrienes B4, C4, D4 and E4 in lung lymph were assayed by radioimmunoassay and high pressure liquid chromatography and remained at baseline values.